カテゴリ： GlobalData, 企業調査

Nanobiotix SA (NANO)：企業の製品パイプライン分析

◆英語タイトル：Nanobiotix SA (NANO) - Product Pipeline Analysis, 2020 Update
◆商品コード：GDME87155PD
◆発行会社（調査会社）：GlobalData
◆発行日：2021年1月
◆ページ数：53
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：フランス
◆産業分野：Medical Devices
◆販売価格オプション（消費税別）
Site License（同一事業所内共有可）USD1,500 ⇒換算￥222,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD2,250 ⇒換算￥333,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Nanobiotix SA (Nanobiotix) designs and manufactures nanomedicines for the treatment of cancer. The company is evaluating its lead product candidate NBTXR3 against soft tissue sarcoma, pancreatic, liver, rectal, prostate, head and neck cancers; Non-small cell lung cancer (NSCLC); recurrent head and neck, lung or liver metastasis. Its product candidate consists of nanoparticles delivered through one time intratumoral injection and are activated by radiation therapy. The company is a spin-off from the University of Buffalo in New York. It has operations in the US, Spain and Germany. Nanobiotix is headquartered in Paris, Ile-de-France, France

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Nanobiotix SA
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Nanobiotix SA Company Overview
Nanobiotix SA Company Snapshot
Nanobiotix SA Pipeline Products and Ongoing Clinical Trials Overview
Nanobiotix SA – Pipeline Analysis Overview
Nanobiotix SA – Key Facts
Nanobiotix SA – Major Products and Services
Nanobiotix SA Pipeline Products by Development Stage
Nanobiotix SA Ongoing Clinical Trials by Trial Status
Nanobiotix SA Pipeline Products Overview
Hensify – Breast Cancer
Hensify – Breast Cancer Product Overview
Hensify – Gastrointestinal Cancer
Hensify – Gastrointestinal Cancer Product Overview
Hensify – Genitourinary Cancer
Hensify – Genitourinary Cancer Product Overview
Hensify – Glioblastoma
Hensify – Glioblastoma Product Overview
Hensify – H&N & Lung Cancer
Hensify – H&N & Lung Cancer Product Overview
Hensify – Head & Neck Cancer
Hensify – Head & Neck Cancer Product Overview
Hensify – Head & Neck Cancer Clinical Trial
Hensify – Liver Cancer
Hensify – Liver Cancer Product Overview
Hensify – Liver Cancer Clinical Trial
Hensify – Lung Cancer
Hensify – Lung Cancer Product Overview
Hensify – Lung Cancer Clinical Trial
Hensify – Prostate Cancer
Hensify – Prostate Cancer Product Overview
Hensify – Prostate Cancer Clinical Trial
Hensify – Rectal Cancer
Hensify – Rectal Cancer Product Overview
Hensify – Rectal Cancer Clinical Trial
Hensify – Soft Tissue Sarcoma
Hensify – Soft Tissue Sarcoma Product Overview
Hensify – Thoracic (Esophageal) Cancer
Hensify – Thoracic (Esophageal) Cancer Product Overview
NanoMag
NanoMag Product Overview
NanoPDT
NanoPDT Product Overview
Nanobiotix SA – Key Competitors
Nanobiotix SA – Key Employees
Nanobiotix SA – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nanobiotix SA, Recent Developments
Oct 23, 2020: Nanobiotix announces third quarter 2020 revenue
Feb 28, 2020: Nanobiotix 2019 Q4 and annual revenues
Jan 07, 2020: NANOBIOTIX announces plan for global phase III Head and Neck Cancer registration trial along with overall development update
Dec 16, 2019: NANOBIOTIX receives the 2019 Prix Galien award for first-in-class HENSIFY
Nov 12, 2019: NANOBIOTIX announces new results from pre-clinical immuno-oncology study at SITC 2019
Oct 25, 2019: NANOBIOTIX announces third quarter 2019 revenue
Sep 04, 2019: Nanobiotix announces half-year financial statements as of June 30, 2019
Jul 19, 2019: Nanobiotix announces second quarter 2019 revenue
Jul 01, 2019: NANOBIOTIX announces new organizational structure as the company enters its next stage after first European market approval
Jul 01, 2019: Nanobiotix announces new organizational structure as the company enters its next stage after first european market approval
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

List of Tables
Nanobiotix SA Pipeline Products and Ongoing Clinical Trials Overview
Nanobiotix SA Pipeline Products by Equipment Type
Nanobiotix SA Pipeline Products by Indication
Nanobiotix SA Ongoing Clinical Trials by Trial Status
Nanobiotix SA, Key Facts
Nanobiotix SA, Major Products and Services
Nanobiotix SA Number of Pipeline Products by Development Stage
Nanobiotix SA Pipeline Products Summary by Development Stage
Nanobiotix SA Ongoing Clinical Trials by Trial Status
Nanobiotix SA Ongoing Clinical Trials Summary
Hensify - Breast Cancer - Product Status
Hensify - Breast Cancer - Product Description
Hensify - Gastrointestinal Cancer - Product Status
Hensify - Gastrointestinal Cancer - Product Description
Hensify - Genitourinary Cancer - Product Status
Hensify - Genitourinary Cancer - Product Description
Hensify - Glioblastoma - Product Status
Hensify - Glioblastoma - Product Description
Hensify - H&N & Lung Cancer - Product Status
Hensify - H&N & Lung Cancer - Product Description
Hensify - Head & Neck Cancer - Product Status
Hensify - Head & Neck Cancer - Product Description
Hensify - Head & Neck Cancer - A Phase Ib/II Study of PEP503 (Radioenhancer) with Radiotherapy in Combination with Concurrent Chemotherapy for Patients with Head and Neck Cancer
Hensify - Head & Neck Cancer - Overall Survival (OS)-based, Randomized, Event-driven Phase II/III Clinical Trial with Standard of Care Radiotherapy Combined with NBTXR3
Hensify - Head & Neck Cancer - PhI Study of NBTXR3 with Intensity Modulated Radiation Therapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Hensify - Liver Cancer - Product Status
Hensify - Liver Cancer - Product Description
Hensify - Liver Cancer - A Phase I-II Study of NBTXR3 Activated by Sterostatic Body Radiation Therapy (SBRT) in the Treatment of Liver Cancers
Hensify - Lung Cancer - Product Status
Hensify - Lung Cancer - Product Description
Hensify - Lung Cancer - Phase I Study of Reirradiation with NBTXR3 for Inoperable Locoregional Recurrent Non-Small Cell Lung Cancer (NSCLC)
Hensify - Prostate Cancer - Product Status
Hensify - Prostate Cancer - Product Description
Hensify - Prostate Cancer - A Phase I-II Dose-escalation Study of NBTXR3 Activated by EBRT or EBRT with Brachytherapy in Patients with Newly Diagnosed Unfavorable Intermediate or High Risk Prostate Adenocarcinoma Treated with Androgen Deprivation
Hensify - Rectal Cancer - Product Status
Hensify - Rectal Cancer - Product Description
Hensify - Rectal Cancer - A Phase Ib/II Study of PEP503 (Radioenhancer) with Radiotherapy, in Combination with Concurrent Chemotherapy for Patients with Locally Advanced or Unresectable Rectal Cancer
Hensify - Soft Tissue Sarcoma - Product Status
Hensify - Soft Tissue Sarcoma - Product Description
Hensify - Thoracic (Esophageal) Cancer - Product Status
Hensify - Thoracic (Esophageal) Cancer - Product Description
NanoMag - Product Status
NanoMag - Product Description
NanoPDT - Product Status
NanoPDT - Product Description
Nanobiotix SA, Key Employees
Nanobiotix SA, Subsidiaries
Glossary

★海外企業調査レポート[Nanobiotix SA (NANO)：企業の製品パイプライン分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Vericel Corp (VCEL)-医療機器分野：企業M&A・提携分析
    Summary Vericel Corp (Vericel) formerly Aastrom Biosciences, Inc. is a medical device company that develops patient-specific expanded cellular therapies to repair and regenerate damaged tissue for the treatment of severe, chronic ischemic cardiovascular diseases. It markets two autologous cell thera …
  • Anglian Group Limited：企業の戦略・SWOT・財務情報
    Anglian Group Limited - Strategy, SWOT and Corporate Finance Report Summary Anglian Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Severn Trent Plc：企業の戦略・SWOT・財務情報
    Severn Trent Plc - Strategy, SWOT and Corporate Finance Report Summary Severn Trent Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Saint-Gobain Ltd：企業の戦略的SWOT分析
    Saint-Gobain Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • CeQur SA：医療機器：M&Aディール及び事業提携情報
    Summary CeQur SA (CeQur) is a medical device company that develops and commercializes insulin delivery systems. The company offers product PAQ, a wearable insulin delivery device, which delivers both basal and bolus doses. Its PAQ product consist two components such as insulin reservoir and messenge …
  • Fugro GeoServices Ltd：企業の戦略的SWOT分析
    Fugro GeoServices Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • GKN plc：企業の戦略・SWOT・財務情報
    GKN plc - Strategy, SWOT and Corporate Finance Report Summary GKN plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Berkem SA：戦略・SWOT・企業財務分析
    Berkem SA - Strategy, SWOT and Corporate Finance Report Summary Berkem SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Aetna Inc：企業のM&A・事業提携・投資動向
    Aetna Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Aetna Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Sensus Healthcare Inc (SRTS)：企業の製品パイプライン分析2018
    Summary Sensus Healthcare Inc (Sensus) designs, manufactures and markets proprietary medical devices for the treatment of various types of cancers and skin diseases. The company offers superficial radiation therapy (SRT) technology based non-surgical treatment options for patients suffering from var …
  • Rush Enterprises, Inc.：企業の戦略・SWOT・財務分析
    Rush Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report Summary Rush Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Poslovni sistem Mercator, d.d.：企業のM&A・事業提携・投資動向
    Poslovni sistem Mercator, d.d. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Poslovni sistem Mercator, d.d. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Praxair Inc (PX)-石油・ガス分野：企業M&A・提携分析
    Summary Praxair Inc (Praxair) is a producer and supplier of industrial gases. The company offers atmospheric gases including oxygen, nitrogen, argon and rare gases, and process gases such as carbon dioxide, helium, hydrogen, electronic gases, specialty gases and acetylene. It also designs and builds …
  • Linamar Corporation：企業の戦略・SWOT・財務分析
    Linamar Corporation - Strategy, SWOT and Corporate Finance Report Summary Linamar Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • PNE Wind AG (PNE3)-エネルギー分野：企業M&A・提携分析
    Summary PNE Wind AG (PNE) is a renewable energy company. It has a presence in the entire value added chain in the wind energy sector. The company develops, manages projects, realizes, finances, and operates wind-farm projects. PNE also offers commercial and technical operating management services fo …
  • Supernus Pharmaceuticals Inc (SUPN)：企業の財務・戦略的SWOT分析
    Supernus Pharmaceuticals Inc (SUPN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Camaieu：企業の戦略・SWOT・財務情報
    Camaieu - Strategy, SWOT and Corporate Finance Report Summary Camaieu - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • GHD Pty Ltd：企業の戦略・SWOT・財務分析
    GHD Pty Ltd - Strategy, SWOT and Corporate Finance Report Summary GHD Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Laboratoire HRA Pharma SAS-製薬・医療分野：企業M&A・提携分析
    Summary Laboratoire HRA Pharma (HRA Pharma) is a healthcare products provider that offers women’s health and endocrinology products. The company offers a wide range of women’s health products which include emergency contraception, uterine fibroids, regular contraception and genital herp products amo …
  • VistaGen Therapeutics Inc (VTGN)：企業の財務・戦略的SWOT分析
    Summary VistaGen Therapeutics Inc (VistaGen) is a clinical stage biopharmaceutical company that develops new generation medicines for depression and neuropsychiatric disorders. The company’s pipeline product, AV-101, currently under Phase 2 clinical development, is an oral N-methyl-D-aspartate recep …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆